242 related articles for article (PubMed ID: 28123121)
1. [Innovation of bisphosphonates for improvement of adherence.].
Takeuchi Y
Clin Calcium; 2017; 27(2):197-202. PubMed ID: 28123121
[TBL] [Abstract][Full Text] [Related]
2. [Bisphosphonate].
Hagino H
Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
[TBL] [Abstract][Full Text] [Related]
3. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
[TBL] [Abstract][Full Text] [Related]
5. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
6. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
[TBL] [Abstract][Full Text] [Related]
7. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
[TBL] [Abstract][Full Text] [Related]
8. Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost.
Chodick G; Moser SS; Goldshtein I
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):359-70. PubMed ID: 27015247
[TBL] [Abstract][Full Text] [Related]
9. Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
Roh YH; Noh JH; Gong HS; Baek GH
J Bone Miner Metab; 2018 Sep; 36(5):589-595. PubMed ID: 28983705
[TBL] [Abstract][Full Text] [Related]
10. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
[TBL] [Abstract][Full Text] [Related]
11. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
12. How to use bisphosphonates safely and optimally.
Jagpal A; Saag KG
Rheumatology (Oxford); 2018 Nov; 57(11):1875-1876. PubMed ID: 29165674
[No Abstract] [Full Text] [Related]
13. Review: Breaking From Bisphosphonates.
Seton M
Arthritis Rheumatol; 2017 Mar; 69(3):494-498. PubMed ID: 27788292
[No Abstract] [Full Text] [Related]
14. Oral bisphosphonate compliance and persistence: a matter of choice?
Silverman SL; Schousboe JT; Gold DT
Osteoporos Int; 2011 Jan; 22(1):21-6. PubMed ID: 20458571
[TBL] [Abstract][Full Text] [Related]
15. [Bisphosphonates (BP) and osteonecrosis of the jaws; continuous treatment with Bisphosphonates should be considered].
Mawatari T
Clin Calcium; 2010 Nov; 20(11):1743-7. PubMed ID: 21066910
[No Abstract] [Full Text] [Related]
16. [Osteoporosis].
Uelbelhart B; Rizzoli R
Rev Med Suisse; 2012 Jan; 8(324):109-10, 112-5. PubMed ID: 23185820
[TBL] [Abstract][Full Text] [Related]
17. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
Horning JA; Czajka J; Uhl RL
Orthopedics; 2010 Dec; 33(12):902. PubMed ID: 21117565
[No Abstract] [Full Text] [Related]
18. [Intermittent long-term administration of intravenous bisphosphonates for treatment of osteoporosis].
Miyakoshi N
Clin Calcium; 2014 Jan; 24(1):93-9. PubMed ID: 24369285
[TBL] [Abstract][Full Text] [Related]
19. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate therapy: how long is long enough?
McClung MR
Osteoporos Int; 2015 May; 26(5):1455-7. PubMed ID: 25609156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
